Jebsen Capital

Jebsen Capital is the corporate venture capital arm of Jebsen and Company, located in Causeway Bay, Hong Kong. The firm focuses on growth-stage investments across various sectors, including automotive, consumer products, beverages, logistics, manufacturing, distribution, and healthcare, with a particular emphasis on opportunities within Greater China. Jebsen Capital aims to capture investment prospects in emerging industries while bolstering the Jebsen Group's existing core businesses. By leveraging the Group's operational expertise and long-term investment strategy, Jebsen Capital also engages in real estate-related projects and enhances internal processes to promote sustainable development within the organization.

Alfons Mensdorff-Pouilly

CEO and Member of Investment Committee

5 past transactions

Razor Group

Venture Round in 2021
Operator of a consumer goods holding company intended to invest and buy profitable brands. The company's marketplace combines advanced data analytics and custom-built technology, an optimized M&A process and in-house e-commerce and finance expertise to find suitable acquisition targets, enabling brands to scale profitable and demonstrate category leadership, better-quality products and customer reviews.

PlusDental

Venture Round in 2021
PlusDental, founded in 2017 and based in Berlin, Germany, specializes in digital orthodontics, focusing on cosmetic cases of malocclusion through the use of clear aligners. The company aims to revolutionize aesthetic orthodontics in Europe by leveraging innovative technology to provide treatments that are convenient and affordable. PlusDental operates in a rapidly expanding market for clear aligners, seeking to enhance accessibility for customers who can benefit from this effective and versatile treatment method. With a team composed of both business professionals and dental experts, PlusDental is committed to improving the orthodontic treatment experience.

BioNTech

Series B in 2019
BioNTech is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. Founded in 2008 and headquartered in Mainz, Germany, the company has pioneered innovative therapies through advanced computational discovery and drug development platforms. BioNTech's oncology pipeline includes various neoantigen-targeted therapies, such as NEO-PV-01 for advanced non-small cell lung cancer and multiple FixVac product candidates for different cancers, including melanoma, prostate cancer, and HPV-positive head and neck cancers. The company also explores mRNA vaccine candidates for infectious diseases and maintains collaborations with prominent pharmaceutical firms. BioNTech Cell & Gene Therapies GmbH, a subsidiary, specializes in developing T cell immunotherapies for cancer treatment.

Cipia

Venture Round in 2018
Cipia, formerly Eyesight Technologies, is a leading provider of intelligent sensing solutions that use edge-based computer vision and AI for safer and better mobility experiences. The company focuses on the automotive in-cabin environment, offering Driver Sense – driver monitoring system, Cabin Sense – occupancy monitoring systems and Fleet Sense- driver monitoring device for fleets. Over a decade of research and development stand behind the company’s proprietary market-leading computer vision technology. Cipia is constantly pushing the boundaries of what intelligent sensing solutions can see and accomplish, for better and safer mobility.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.